In this episode of the Crux of Neuro, Liz Moyles is joined by Deanna Harshman, CEO of Cala Health, to explore how non-invasive neurostimulation is changing the way we think about treating essential tremor and Parkinson’s disease. From her early career in chemical engineering and time working in deep brain stimulation to leading Cala Health, Deanna shares the journey behind Cala’s approach to treating hand tremor without surgery. She explains how the company’s watch-like device uses transcutaneous afferent pattern stimulation (TAPS) to measure each patient’s tremor and deliver personalised stimulation designed to disrupt pathological oscillations in the brain. The conversation also explores what it takes to move a new neurological therapy from an interesting scientific concept to a treatment that patients can actually use — from clinical evidence and physician adoption to FDA clearance, reimbursement and designing technology around real patient needs.